Phibro Animal Health (NASDAQ:PAHC) Announces Earnings Results, Beats Expectations By $0.15 EPS

Phibro Animal Health (NASDAQ:PAHC) posted its earnings results on Wednesday. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15, FiscalAI reports. The company had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health updated its FY 2026 guidance to 2.640-2.810 EPS.

Phibro Animal Health Price Performance

PAHC traded up $0.72 during trading on Friday, reaching $43.76. 380,574 shares of the company traded hands, compared to its average volume of 277,290. The company has a market cap of $1.77 billion, a P/E ratio of 37.09, a PEG ratio of 1.24 and a beta of 0.81. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. Phibro Animal Health has a 12-month low of $16.16 and a 12-month high of $44.35. The firm has a fifty day simple moving average of $39.58 and a 200 day simple moving average of $30.66.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th will be issued a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is 40.68%.

Insider Buying and Selling at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 16,075 shares of Phibro Animal Health stock in a transaction on Monday, October 20th. The shares were sold at an average price of $40.38, for a total value of $649,108.50. Following the sale, the chief executive officer directly owned 23,899 shares in the company, valued at approximately $965,041.62. The trade was a 40.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 67,336 shares of company stock worth $2,734,588 in the last three months. 50.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phibro Animal Health

Several large investors have recently made changes to their positions in the company. State of Wyoming boosted its stake in Phibro Animal Health by 148.8% during the second quarter. State of Wyoming now owns 6,608 shares of the company’s stock valued at $169,000 after buying an additional 3,952 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Phibro Animal Health by 768.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after acquiring an additional 4,079 shares during the last quarter. State of Tennessee Department of Treasury boosted its position in shares of Phibro Animal Health by 18.6% during the 2nd quarter. State of Tennessee Department of Treasury now owns 26,743 shares of the company’s stock valued at $683,000 after acquiring an additional 4,200 shares during the last quarter. Oxford Asset Management LLP purchased a new position in shares of Phibro Animal Health in the second quarter valued at $485,000. Finally, Lazard Asset Management LLC increased its position in Phibro Animal Health by 3,392.3% in the second quarter. Lazard Asset Management LLC now owns 92,441 shares of the company’s stock worth $2,360,000 after purchasing an additional 89,794 shares during the last quarter. 99.34% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 29th. Bank of America lifted their target price on Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research report on Friday, August 29th. JPMorgan Chase & Co. upped their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a research report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.